China Resources Pharmaceutical extends connected loan agreements with CR Holdings

China Resources Pharmaceutical Group Limited announced the signing of new Framework Loan Agreements 2025 with CRI and CR Holdings on December 15, 2025. These agreements, effective from January 1, 2026, until December 31, 2028, replace the expiring 2023 agreements and allow the group to lend surplus cash to other China Resources Group companies. CR Holdings, holding approximately 53.40% interest in the company, and CRI, the controlling shareholder of CR Holdings, are connected persons, making these continuing connected transactions.

The maximum aggregate daily outstanding amount owed to the group under these new agreements is capped at RMB1,300m for each of the years ending December 31, 2026, 2027, and 2028. This compares to historical daily outstanding amounts of RMB0m in 2023, RMB400.3m in 2024, and RMB300.5m for the nine months ended September 30, 2025. The transactions are subject to reporting, annual review, and announcement requirements, but are exempt from independent shareholders' approval as applicable size test percentage ratios are between 0.1% and 5%.

The interest rates for these advances are determined with reference to HIBOR for HKD, SOFR for USD, and a prevailing market rate for RMB, including a margin. All advances are guaranteed by CR Holdings and/or CRI, with a guarantee fee of 0.05% per annum on the advance amount. The repayment date for advances made under the Offshore Framework Loan Agreement 2025 is no later than six months after the advance date.